Procalcitonin Level and Kinetics in Children With Bacterial Infections - Full Text View

Procalcitonin Level and Kinetics in Children With Bacterial Infections

This study is not yet open for participant recruitment.
Verified by Shaare Zedek Medical Center, July 2008

Sponsored by:	Shaare Zedek Medical Center
Information provided by:	Shaare Zedek Medical Center
ClinicalTrials.gov Identifier:	NCT00714402

Purpose

The purposes of this study are:

To determine whether procalcitonin level at admission of pediatric patients with bacterial infections can be used as a marker for prediction of defervescence and hospitalization length
To examine the kinetics of procalcitonin in pediatric patients with bacterial infections and persistent fever

Condition

Bacterial Infections
Bacteremia
Meningitis
Urinary Tract Infection
Mastoiditis
Lobar Pneumonia
Septic Arthritis
Cellulitis
Osteomyelitis

MedlinePlus related topics:

Bacterial Infections Cellulitis Meningitis Pneumonia Urinary Tract Infections

ChemIDplus related topics:

Procalcitonin

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective

Official Title:	Procalcitonin Level as a Prognostic Marker and Its' Kinetics in Children With Bacterial Infections

Further study details as provided by Shaare Zedek Medical Center:

Primary Outcome Measures:

time to defervescence [ Time Frame: discharge ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

length of hospitalization [ Time Frame: discharge ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

whole blood

Estimated Enrollment:	50
Study Start Date:	August 2008

Groups/Cohorts

children with proven of probable invasive bacterial infections

Eligibility

Ages Eligible for Study:	up to 16 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

hospitalized patients at date of admission

Criteria

Inclusion Criteria:

Positive blood, urine, synovial, bone, pleural effusion, abscess or CSF culture
Cellulitis, lobar pneumonia, osteomyelitis,

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00714402

Contacts


Contact: Yechiel Schlesinger, Dr	97226555147	s.yechiel@gmail.com

Contact: Orli Megged, Dr	97226666340	orlimegged@yahoo.com

Locations


Israel, POB 3235
	Shaare Zedek Medical Center	Not yet recruiting
	Jerusalem, POB 3235, Israel, 91031
	Contact: Yechiel Schlesinger s.yechiel@gmail.com

Sponsors and Collaborators

Shaare Zedek Medical Center

Investigators


Principal Investigator:	Yechiel Schlesinger, MD	Shaare Zedek Medical Center

More Information

Publications:

Le Moullec JM, Jullienne A, Chenais J, Lasmoles F, Guliana JM, Milhaud G, Moukhtar MS. The complete sequence of human preprocalcitonin. FEBS Lett. 1984 Feb 13;167(1):93-7.

Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993 Feb 27;341(8844):515-8.

Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial. Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93. Epub 2006 Apr 7.

Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, Widmer I, Neidert S, Blum CA, Schönenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Müller B; ProHOSP study group. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res. 2007 Jul 5;7:102.

Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505. Epub 2007 Dec 20.

Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006 Mar;32(3):469-72. Epub 2006 Feb 14.

Seligman R, Meisner M, Lisboa TC, Hertz FT, Filippin TB, Fachel JM, Teixeira PJ. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care. 2006;10(5):R125.

Hatherill M, Tibby SM, Turner C, Ratnavel N, Murdoch IA. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit Care Med. 2000 Jul;28(7):2591-4.

Responsible Party:	Shaare Zedek Medical Center ( Yechiel Schlesinger )
Study ID Numbers:	pct.ctil
First Received:	July 9, 2008
Last Updated:	July 11, 2008
ClinicalTrials.gov Identifier:	NCT00714402
Health Authority:	Israel: Helsinki committee

Keywords provided by Shaare Zedek Medical Center:

UTI

Study placed in the following topic categories:

Bacterial Infections

Urinary Tract Infections

Arthritis, Infectious

Bone Diseases

Ear Diseases

Meningitis

Gram-Positive Bacterial Infections

Cellulitis

Urologic Diseases

Respiratory Tract Infections

Respiratory Tract Diseases

Musculoskeletal Diseases

Streptococcal Infections

Pneumonia, Bacterial

Arthritis

Connective Tissue Diseases

Suppuration

Mastoiditis

Systemic Inflammatory Response Syndrome

Otorhinolaryngologic Diseases

Skin Diseases

Joint Diseases

Pneumonia, Pneumococcal

Otitis Media

Central Nervous System Diseases

Bacteremia

Pneumococcal Infections

Inflammation

Sepsis

Skin Diseases, Infectious

Additional relevant MeSH terms:

Communicable Diseases

Pathologic Processes

Nervous System Diseases

Infection

Bone Diseases, Infectious

ClinicalTrials.gov processed this record on September 19, 2008